JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY HYDERABAD Pharm. D V Year PHARMACOEPIDEMIOLOGY AND PHARMACOECONOMICS Previous Question Paper (July/August - 2021 - R08)

Pharmacoepidemiology originated from the convergence of clinical pharmacology and epidemiology, gaining prominence in the 1970s and 1980s as a response to the need for systematic post-marketing surveillance of drug safety. It evolved from simple case reports and anecdotal observations to rigorous scientific methodologies designed to measure the risks and benefits of medications in large populations. The evaluation of pharmacoepidemiology involves assessing the validity of drug-exposure measurements, the accuracy of health outcome data, and the control of confounding variables to ensure that observed associations between drugs and clinical events are causal rather than spurious.

The evaluation process relies on several key components:

• Study Design: Utilization of observational designs such as cohort studies, case-control studies, and case-crossover designs to evaluate drug effects in real-world settings.
• Data Quality: Assessment of the sensitivity, specificity, and positive predictive value of diagnostic codes and medication records.
• Bias Mitigation: Application of statistical techniques like propensity score matching, instrumental variable analysis, and sensitivity analysis to address selection bias, information bias, and confounding by indication.

Ad hoc data sources refer to information collected for purposes other than research, which are subsequently utilized for pharmacoepidemiological analysis. These sources are not pre-designed for epidemiological studies but provide valuable real-world evidence. Examples include:

• Electronic Health Records (EHRs): Clinical notes and laboratory results recorded during routine patient care.
• Administrative Claims Data: Billing records from pharmacies, hospitals, and insurance providers used for reimbursement purposes.
• Patient Registries: Databases created for disease management or quality improvement that incidentally capture drug exposure data.
• Vital Statistics: Death certificates and birth registries that can be linked to medication history to study long-term outcomes.

While ad hoc sources offer large sample sizes and cost-effectiveness, they require careful validation because they often lack specific clinical details, such as medication adherence or over-the-counter drug use, which are essential for precise epidemiological assessment.

Pharmacoepidemiology is the study of the use and effects of drugs in large populations. Its primary aim is to bridge the gap between clinical pharmacology and epidemiology, focusing on the clinical outcomes of drug therapy in real-world settings rather than controlled clinical trials.

The applications include:

• Identifying previously unrecognized adverse drug reactions (ADRs) or rare side effects.
• Quantifying the benefit-risk ratio of medications in diverse patient populations.
• Evaluating the patterns of drug utilization and adherence in clinical practice.
• Providing data for regulatory decision-making, such as drug labeling changes or withdrawals.
• Supporting evidence-based medicine by comparing the effectiveness of different therapeutic interventions.

Regarding outcome measures, these are the variables used to assess the clinical, economic, or humanistic impact of a drug. They are categorized as:

• Clinical outcomes: Mortality, morbidity, or physiological markers (e.g., blood pressure, HbA1c).
• Economic outcomes: Direct and indirect costs associated with treatment, often measured via cost-effectiveness or cost-utility analysis.
• Humanistic outcomes: Patient-reported outcomes (PROs) such as quality of life, functional status, and patient satisfaction.

Drug use measures are quantitative tools used to describe how medications are prescribed, dispensed, and consumed. Common metrics include:

• Defined Daily Dose (DDD): The assumed average maintenance dose per day for a drug used for its main indication in adults.
• Prescription-based measures: Number of prescriptions per capita or per patient, and duration of therapy.
• Adherence measures: Medication Possession Ratio (MPR) or Proportion of Days Covered (PDC), which calculate the extent to which a patient's actual drug intake matches the prescribed regimen.